BP Koirala Institute of Health Sciences, Ghopa, Dharan, Nepal.
Trop Med Int Health. 2010 Jul;15 Suppl 2:21-8. doi: 10.1111/j.1365-3156.2010.02518.x. Epub 2010 May 6.
OBJECTIVE: Nepal reports a visceral leishmaniasis (VL) incidence of 5 per 10 000 per year on the basis of notification by health facilities, but little community-based epidemiological information exists. We report data on prevalence rates of Leishmania donovani infection in ten communities in East Nepal. METHODS: Ten clusters with highest VL incidence rates were purposefully selected in Nepal. All households were mapped and socio-demographic data and data on past VL incidence were collected. An exhaustive serological survey was performed of individuals aged >2 years, by collecting finger prick blood on filter paper in November-December 2006. The samples were tested by direct agglutination, and a titre >or=1:1600 was taken as marker of infection. A generalized estimating equation (GEE) model was used to assess risk factors for Direct Agglutination Test (DAT) positivity taking into account the clustering at household and village level. RESULTS: The sero-survey (n = 5397) showed an infection prevalence rate of 9%, (range 5-15% per cluster) with higher prevalence in men (9.9%) than in women (8.3%) (P = 0.049). Male gender, increasing age and poverty were significant risk factors in the final GEE model. CONCLUSION: Leishmania infection rate in high-transmission areas in Nepal is associated with gender, age and socio-economic status.
目的:根据卫生机构的报告,尼泊尔每年每 10 000 人中有 5 人患有内脏利什曼病(VL),但很少有基于社区的流行病学信息。我们报告了尼泊尔东部 10 个社区中利什曼原虫感染流行率的数据。
方法:在尼泊尔,有目的选择了 VL 发病率最高的 10 个集群。对所有家庭进行了绘图,并收集了社会人口统计学数据和过去 VL 发病率数据。2006 年 11 月至 12 月,对年龄>2 岁的个体进行了全面的血清学调查,通过在滤纸上采集指尖血进行。用直接凝集试验对样本进行检测,将效价>或=1:1600 作为感染的标志物。考虑到家庭和村庄层面的聚类,使用广义估计方程(GEE)模型评估了直接凝集试验(DAT)阳性的危险因素。
结果:血清调查(n=5397)显示感染率为 9%(每个集群的范围为 5-15%),男性(9.9%)的感染率高于女性(8.3%)(P=0.049)。在最终的 GEE 模型中,男性性别、年龄增长和贫困是显著的危险因素。
结论:尼泊尔高传播地区的利什曼原虫感染率与性别、年龄和社会经济地位有关。
Trop Med Int Health. 2010-5-6
Trop Med Int Health. 2010-5-6
J Commun Dis. 2006-3
Trans R Soc Trop Med Hyg. 2011-9-1
Kathmandu Univ Med J (KUMJ). 2006
Trop Med Int Health. 2004-12
Pathogens. 2025-2-4
Expert Rev Mol Med. 2025-1-9
Front Immunol. 2021